stars 1 stars 2 stars 3

3PBIOVIAN service offering includes microbial and mammalian protein expression platforms, viral vector production for adenoviruses and adeno-associated viruses, cell therapy, and plasmid DNA production, with the provision for fill and finish services for recombinant proteins and viral vectors. Leveraging a combined track record of 40 years in process development and analytical methods development, complemented by the experience in process scale-up, GMP manufacturing, and commercial supply, 3PBIOVIAN is equipped to offer comprehensive manufacturing services at all stages, encompassing Drug Substance and Drug Product. Manufacturing sites in Pamplona-Noáin, Spain, and Turku, Finland seamlessly support the diverse needs of clients, covering pre-clinical and clinical supply to full-scale commercial manufacturing.

3PBIOVIAN Questions

The 3PBIOVIAN annual revenue was $81 million in 2026.

Tim Cinq-Mars is the Associate Director of Business Development of 3PBIOVIAN.

298 people are employed at 3PBIOVIAN.

Top 3PBIOVIAN Employees

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users